Clinical Trials – Page 12

Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher

4 months ago talkbio0Tagged Clinical Trials, Colorectal Carcinoma, Exelixis, regorafenib, STELLAR-303, surge, Tecentriq, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

4 months ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

4 months ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

Zealand Pharma’s Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks

4 months ago talkbio0Tagged Clinical Trials, Dapiglutide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Obesity, Safety, Weight Loss, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1; GLP-2; weight loss; obesity; phase 1b trial; clinical trial; dual agonist; safety

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

4 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

4 months ago talkbio0Tagged ABS-0871, ABS-1230, Actio, Biosciences, Charcot-Marie-Tooth Disease, Clinical Trials, Drugs, Orphan, Epilepsy, Infrequent, Inhibitor, KCNT1 gene, Regeneron, Series B financing, TRPV4 protein, human

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

4 months ago talkbio0Tagged BioNTech, BNT211, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Clinical Trials, Gaithersburg, layoffs, Manufacturing Facilities, Maryland (geographic location)

BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

4 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS

4 months ago talkbio0Tagged AbbVie, Antineoplastic Agents, azacitidine, Clinical Research, Clinical Trials, Miller Dieker syndrome, MYELODYSPLASTIC SYNDROME, Phase 3 trial, Roche (company), Venclexta, venetoclax, Verona

Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug

Sarepta Halts Duchenne Gene Therapy in Some Patients After Second Death

4 months ago talkbio0Tagged Clinical Trials, ELEVIDYS, gene therapy, Liver Failure, Acute, Muscular Dystrophy, Duchenne, patient safety, Therapeutic immunosuppression, Unable to walk (finding), United States Food and Drug Administration

Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; Elevidys; acute liver failure; non-ambulatory patients; FDA; clinical trial pause; immunosuppression; patient safety